Inhibition of tumour growth in vivo by two NSCLC cell lines expressing wild-type EphA3, but not EphA3 mutants, shows that the EphA3 can act as a tumour suppressor in lung cancer [64]. Here, EPHA3 is linked to lung carcinoma.